1-20 of 23
Francesco Bertoni
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies

Francesca Zammarchi, Karin E. Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (4): 520–531.
https://doi.org/10.1158/1535-7163.MCT-23-0506
Published: 02 April 2024
View articletitled, ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Open the PDF for ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms

Alberto J. Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua A. Mensah, Filippo Spriano, Antonella Zucchetto, Francesca M. Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone Pittau, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R. Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 368–380.
https://doi.org/10.1158/1535-7163.MCT-23-0068
Published: 04 March 2024
View articletitled, ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms
Open the PDF for ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms in another window
Includes: Supplementary data
Journal Articles

Abstract C144: MEN1703/SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells

Afua A. Mensah, Alessandro Ghiringhelli, Giulio Sartori, Filippo Spriano, Chiara Tarantelli, Luciano Cascione, Andrea Rinaldi, Alberto A. Arribas, Daniela Bellarosa, Monica Binaschi, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C144.
https://doi.org/10.1158/1535-7163.TARG-23-C144
Published: 01 December 2023
View articletitled, Abstract C144: MEN1703/SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells
Journal Articles

Abstract C139: The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines

Francesca Guidetti, Alberto J. Arribas, Eleonora Cannas, Emanuele Zucca, Anastasios Stathis, Reinhard von Roemeling, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C139.
https://doi.org/10.1158/1535-7163.TARG-23-C139
Published: 01 December 2023
View articletitled, Abstract C139: The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines
Journal Articles

Abstract B170: The in vitro anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition

Giulio Sartori, Filippo Spriano, Luciano Cascione, Chiara Tarantelli, Alberto J. Arribas, Luca Aresu, Davide Rossi, Giovanna Damia, Massimo Broggini, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B170.
https://doi.org/10.1158/1535-7163.TARG-23-B170
Published: 01 December 2023
View articletitled, Abstract B170: The in vitro anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition
Journal Articles

Abstract C112: L1CAM targeting antibody-based therapy as a novel approach for L1CAM  positive lymphomas

Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Elisa Civanelli, Afua A. Mensah, Chiara Tarantelli, Stefano Pileri, Flavio Mehli, Gunther Spohn, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C112.
https://doi.org/10.1158/1535-7163.TARG-23-C112
Published: 01 December 2023
View articletitled, Abstract C112: L1CAM targeting antibody-based therapy as a novel approach for L1CAM  positive lymphomas
Journal Articles

Abstract B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models

Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Filippo Spriano, Afua A. Mensah, Luciano Cascione, Alberto J Arribas, Anastasios Stathis, Karolina Niewola-Staszkowska, Giusy Di Conza, Michael Lahn, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B165.
https://doi.org/10.1158/1535-7163.TARG-23-B165
Published: 01 December 2023
View articletitled, Abstract B165: A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3Kδ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models
Journal Articles

Abstract P073: Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors

Francesca Guidetti, Alberto J. Arribas, Filippo Spriano, Laura Barnabei, Reinhard von Roemeling, Elizabeth Martinez, Emanuele Zucca, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P073.
https://doi.org/10.1158/1535-7163.TARG-21-P073
Published: 01 December 2021
View articletitled, Abstract P073: Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors
Journal Articles

Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells

Afua Adjeiwaa Mensah, Filippo Spriano, Eugenio Gaudio, Annalisa Bonifacio, Emanuela Lovati, Claudio Pietra, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B009.
https://doi.org/10.1158/1535-7163.TARG-19-B009
Published: 01 December 2019
View articletitled, Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells
Journal Articles

Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma

Alberto J. Arribas, Sara Napoli, Eugenio Gaudio, Luciano Cascione, Alessandra Di Veroli, Chiara Tarantelli, Filipppo Spriano, Antonella Zucchetto, Francesca Rossi, Giulio Sartori, Andrea Rinaldi, Anastasios Stathis, Georg Stussi, Valter Gattei, Gabriele Cruciani, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A127.
https://doi.org/10.1158/1535-7163.TARG-19-A127
Published: 01 December 2019
View articletitled, Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma
Journal Articles

Abstract C097: Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles: A new class of antimitotic agents

Virginia Spanò, Daniele Giallombardo, Alessandra Montalbano, Anna Carbone, Eugenio Gaudio, Roberta Bortolozzi, Ruoli Bai, Giampietro Viola, Ernest Hamel, Francesco Bertoni, Paola Barraja
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C097.
https://doi.org/10.1158/1535-7163.TARG-19-C097
Published: 01 December 2019
View articletitled, Abstract C097: Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles: A new class of antimitotic agents
Journal Articles

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas

Valentina Restelli, Monica Lupi, Rosaria Chilà, Micaela Vagni, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Francesco Bertoni, Giovanna Damia, Laura Carrassa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (7): 1255–1264.
https://doi.org/10.1158/1535-7163.MCT-18-0919
Published: 01 July 2019
View articletitled, DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Open the PDF for DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity

Chiara Tarantelli, Elena Bernasconi, Filippo Spriano, Petra Hillmann, Eugenio Gaudio, Luciano Cascione, Ivo Kwee, Doriano Fabbro, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B041.
https://doi.org/10.1158/1535-7163.TARG-17-B041
Published: 01 January 2018
View articletitled, Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity
Journal Articles

Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103

Filippo Spriano, Chiara Tarantelli, Alberto Arribas, Eugenio Gaudio, Luciano Cascione, Luca Aresu, Emanuele Zucca, Davide Rossi, Anastasios Stathis, Maximilien Murone, Dirk Weber, Rajwinder Lehal, Freddy Radtke, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B061.
https://doi.org/10.1158/1535-7163.TARG-17-B061
Published: 01 January 2018
View articletitled, Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103
Journal Articles

Abstract B182: The novel tyrosine kinase inhibitors UJ26 and UJ30 are active in solid tumor and hematologic cancer cell lines

Chiara Tarantelli, Eugenio Gaudio, Andrea Unzue, Pawel Sledz, Hillarie Ekeh, Elena Bernasconi, Filippo Spriano, Cristina Nevado, Amedeo Caflisch, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B182.
https://doi.org/10.1158/1535-7163.TARG-17-B182
Published: 01 January 2018
View articletitled, Abstract B182: The novel tyrosine kinase inhibitors UJ26 and UJ30 are active in solid tumor and hematologic cancer cell lines
Journal Articles

Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type

Chiara Tarantelli, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Andrea Testa, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A179.
https://doi.org/10.1158/1535-7163.TARG-17-A179
Published: 01 January 2018
View articletitled, Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type
Journal Articles

Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas

Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Luciano Cascione, Elena Bernasconi, Petra Hillmann, Georg Stussi, Doriano Fabbro, Emanuele Zucca, Andreas Wicki, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A117.
https://doi.org/10.1158/1535-7163.TARG-15-A117
Published: 01 December 2015
View articletitled, Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
Journal Articles

Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations

Elena Bernasconi, Eugenio Gaudio, Chiara Tarantelli, Luciano Cascione, Ivo Kwee, Andrea Rinaldi, Afua A. Mensah, Anastasios Stathis, Matthias Ocker, Emanuele Zucca, Bernard Haendler, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B76.
https://doi.org/10.1158/1535-7163.TARG-15-B76
Published: 01 December 2015
View articletitled, Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations
Journal Articles

Abstract B77: The BET bromodomain inhibitor OTX015 (MK-8628) in mantle cell lymphoma (MCL): in vivo activity and identification of novel combinations to overcome adaptive resistance

Eugenio Gaudio, Elena Bernasconi, Chiara Tarantelli, Luciano Cascione, Ivo Kwee, Andrea Rinaldi, Maurilio Ponzoni, Maria E. Riveiro, Emanuele Zucca, Francesco Bertoni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B77.
https://doi.org/10.1158/1535-7163.TARG-15-B77
Published: 01 December 2015
View articletitled, Abstract B77: The BET bromodomain inhibitor OTX015 (MK-8628) in mantle cell lymphoma (MCL): in vivo activity and identification of novel combinations to overcome adaptive resistance
Journal Articles

Abstract C193: Combining ibrutinib with Chk1 inhibitors as a new therapeutic strategy for mantle cell lymphoma

Valentina Restelli, Micaela Vagni, Monica Lupi, Francesco Bertoni, Giovanna Damia, Laura Carrassa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C193.
https://doi.org/10.1158/1535-7163.TARG-15-C193
Published: 01 December 2015
View articletitled, Abstract C193: Combining ibrutinib with Chk1 inhibitors as a new therapeutic strategy for mantle cell lymphoma